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Abstract
Background: GP-BAR1, a member G protein coupled receptor superfamily, is a cell surface bile acid-activated receptor
highly expressed in the ileum and colon. In monocytes, ligation of GP-BAR1 by secondary bile acids results in a cAMP-
dependent attenuation of cytokine generation.
Aims: To investigate the role GP-BAR1 in regulating intestinal homeostasis and inflammation-driven immune dysfunction in
rodent models of colitis.
Methods: Colitis was induced in wild type and GP-BAR1
2/2 mice by DSS and TNBS administration. Potential GP-BAR1
agonists were identified by in silico screening and computational docking studies.
Results: GP-BAR1
2/2 mice develop an abnormal morphology of colonic mucous cells and an altered molecular architecture
of epithelial tight junctions with increased expression and abnormal subcellular distribution of zonulin 1 resulting in
increased intestinal permeability and susceptibility to develop severe colitis in response to DSS at early stage of life. By in
silico screening and docking studies we identified ciprofloxacin as a GP-BAR1 ligand. In monocytes, ciprofloxacin increases
cAMP concentrations and attenuates TNFa release induced by TLR4 ligation in a GP-BAR1 dependent manner. Treating mice
rendered colitic by TNBS with ciprofloxacin and oleanolic acid, a well characterized GP-BAR1 ligand, abrogates signs and
symptoms of colitis. Colonic expression of GP-BAR1 mRNA increases in rodent models of colitis and tissues from Crohn’s
disease patients. Flow cytometry analysis demonstrates that <90% of CD14+ cells isolated from the lamina propria of TNBS-
treated mice stained positively for GP-BAR1.
Conclusions: GP-BAR1 regulates intestinal barrier structure. Its expression increases in rodent models of colitis and Crohn’s
disease. Ciprofloxacin is a GP-BAR1 ligand.
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Introduction
Bile acids play an essential role in integrating multiple
homeostatic functions in the liver and gastrointestinal tract. In
recent years these end-product of cholesterol metabolism have
been shown to signal through activation of variety of nuclear and
cell surface receptors [1]. Activation of Farnesoid-x-receptor
(FXR), pregnane-x-receptor (PXR), and constitutive androstane
receptor (CAR), along with the vitamin D receptor (VDR), by
primary bile acids chenodeoxycholic acid (CDCA) and colic acid
(CA) elicits a series of genomic effects that have been deemed
essential for regulation of lipid, cholesterol and bile acid
homeostasis, local immune response and insulin signalling in
intestinal and liver tissues [1,2]. Knocking down the expression of
FXR, the main bile acid receptor, results in a multilevel
dysregulation of glucose, lipid, cholesterol and protein metabolism,
highlighting the essential role of this receptor in maintaining
homeostasis in entero-hepatic tissues [1,2].
In addition, bile acids exert non-genomic effects [1,2]. These
non-genomic effects have been ascribed to the activation of a cell
surface receptor named TGR5 or M-BAR, a member of the
rhodopsin-like superfamily of G protein coupled receptor (GPCR),
recently christened as a bile acid-activated GPCR (GP-BAR1)
[3,4]. GP-BAR1 is restricted to a limited number of tissues, with
the highest expression detected in brown adipose tissue, spleen,
macrophages/monocytes, gallbladder and intestine [3–5]. In the
small and large intestine, GP-BAR1 has been detected in the
enteric ganglia of the myenteric and submucosal plexus, in the
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and villi, while in the cecum and colon the receptor is expressed,
thought at lower, in muscle layers and mucosa [6].
In target cells, GP-BAR1 activation by secondary bile acids,
lithocolic acid (LCA) and tauro-LCA (TLCA), increases the
intracellular concentrations of cyclic adenosine monophosphate
(cAMP) and causes the receptor internalization [1–4]. In intestinal
endocrine L-cells that are higly enriched in receptor expression,
GP-BAR1 activation by bile acids and dietary agents stimulates
the secretion of glucagon-like peptide (GLP)-1, an insulinotropic
hormone that regulates insulin and glucagon secretion along with
gastrointestinal motility and appetite [1–4,7].
In addition to its intestinal localization, GP-BAR1 has been
detected in peripheral blood derived macrophages and liver
macrophages where it exerts an immune-modulatory activity
[2,4]. This activity is inhibitory in nature and manifests itself by
attenuation of macrophage’s effector functions including reduction
of phagocytic activity as well and generation of lipopolysaccharide
(LPS)-stimulated cytokines (TNF-a, IL-1a, IL-1b, IL-6, and IL-89
[2,8].
Despite its role in integrating intestinal homeostasis and glucose
metabolism is well defined, it is not known whether GP-BAR1
participates into local regulation of intestinal inflammation and
whether its ablation would manifest by an exaggerated inflamma-
tory response to intestinal antigens. Because the expression of GP-
BAR1 is highly restricted to the intestine and identification of a
regulatory role would be of interest to ground intestine-specific
anti-inflammatory therapies, we have investigated whether GP-
BAR1 plays a functional role in regulating intestinal homeostasis
and inflammation-driven immune response.
Materials and Methods
C57BL6 were from Harlan Nossan (Udine, Italy) and GP-
BAR1 null mice (GP-BAR1-B6=GP-BAR1
2/2 mice, generated
directly into C57BL/6NCrl background), and congenic littermates
on C57BL/6NCrl mice were kindly gifted by Dr. Galya Vassileva
(Schering-Plough Research Institute, Kenilworth) [9]. Mice were
housed under controlled temperatures (22uC) and photoperiods
(12:12-hour light/dark cycle), allowed unrestricted access to
standard mouse chow and tap water and allowed to acclimate to
these conditions for at least 5 days before inclusion in an
experiment. Protocols were approved by the University of Perugia
Animal Care Committee. The ID for this project is #98/2010-B.
The authorization was released to Prof. Stefano Fiorucci, as a
principal investigator, on May 19, 2010. GLUTag cells were
developed originally by Dr. Daniel Druker and were kindly
provided by Dr. Fiona Gribble (University Cambridge, UK).
Human colon samples were obtained from 6 patients with Crohn’s
disease (2 female; mean age 43, range 34–61) and 6 subjects (1
female; mean age 51; range 43–64) who underwent colonic
resection for colon adenocarcinoma. An informed written consent
on the use of biopsies from removed tissues was obtained from
each patient. Crohn’s disease patients were treated with
azathioprine (5 patients) and adalimumab (3 patients) and, in
three patients, the reason for surgery was an ileal stricture
associated with an abdominal abscess. Control colon samples were
obtained from biopsies taken at the intact margins of colonic
resections.
Intestinal permeability studies
Assessment of intestinal permeability towards 4000 Da fluores-
cent dextran-FITC (DX-4000-FITC) (Sigma-Aldrich, St. Louis,
MO) was measured as described by Wang Q., et al. [10]. Briefly,
mice were fasted for 6 h and then given DX-4000-FITC by
gavage (500 mg/kg body weight, 125 mg (ml). After 4 h, 120 mlo f
blood was collected from the hearth. The blood was centrifuged at
4uC, 12.000 g for 3 minutes. Plasma was diluted in an equal
volume of PBS and analysed for DX-4000-FITC concentration
with a fluorescence spectrophotometer (HTS-7000 Plus- plate-
reader; Perkin Elmer, Wellesey, MA) at an excitation wavelength
of 485 nm and emission wavelength of 535 nm. A standard curve
was prepared by diluting FITC-dextrane in non-treated plasma
diluted with PBS (1:3 v/v).
Animal models of colitis, histopathology analysis and
MPO activity
TNBS and DSS colitis were induced as described [11]. Five
days after TNBS, 1.5 mg/mouse, or DSS, 5% in drinking water,
administration, mice were sacrificed, colons were removed and
immediately frozen in liquid nitrogen and stored at 280uC and in
formalin. Ciprofloxacin (30 mg/kg i.p.) or oleanolic acid, 0, 1, 1
and 10 mg/kg orally (per os) (both from Sigma-Aldrich, St. Louis,
MO) were administered daily for the duration of the experiment.
The colon’s macroscopic appearance was inspected at the end of
the study and graded taking into considering the presence of
indurations, edema, thickness and severity of mucosal haemor-
rhages. Grading was performed in a blinded fashion. For histologic
analysis, human and mouse colon samples were fixed in buffered
formalin, and routinely prepared 5-mm sections, stained with
hematoxylin and eosin (H&E) and mouse colon injury scored as
described previously [11,12].
Immuno-histochemistry and immuno-fluorescence
studies
Human and mouse colon samples were removed and fixed in
10% buffered formalin phosphate, embedded in paraffin and
sections (7 mm thickness) processed for immunohistochemistry.
Briefly, sections were deparaffinized and, after antigen retrieval,
washed in PBS, soaked in 3% H2O2 for 8 h, and then incubated
with 5% bovine serum albumin in PBS with Triton X-100 (0,1%)
for 30 min. Sections were then incubated with 10 mg/ml of anti-
GP-BAR1 primary antibody (NBP1-39749, Novus Biologicals) or
8 mg/ml rabbit anti-zonulin-1 (Invitrogen), in PBS with 0.3%
Triton X-100 and 1% bovine serum albumin, at RT for 2 h. The
sections were incubated with biotinylated anti-rabbit IgG 1:200
(Vector) and then processed by the avidin-biotin-peroxidase
method with Vectastain ABC kit (Vector, UK). Diaminobenzidine
was used as chromogen. For immunoflurescence, after antigen
retrieval by proteinase K, sections were incubated with 8 mg/ml
rabbit anti-zonulin-1 in PBS with 0.3% Triton X-100 and 1%
bovine serum albumin, at RT for 2 h, and then stained with anti
rabbit, phycoerythrin (PE)-conjugated, IgG 1:200. Cytokine
plasma and intestinal levels were measured by commercial ELISA
kits (Multi-analyte ELISArray Kit; SAbiosciences A, Qiagen).
RT-PCRs
Methods for RNA isolation, cDNAs amplification and PCR
conditions and analysis have been described previously [13]. All
PCR primers were designed with the PRIMER3-NEW software
using published sequence data from the NCBI database. Primers
were synthesized by MWG BIOTECH. Human (h) and murine
(m) sense and antisense primers were as following: mTNFa:
(s)acggcatggatctcaaagac and (as) gtgggtgaggagcacgtagt; mIL1b:
tcacagcagcacatcaacaa and tgtcctcatcctcgaaggtc; mIL6: ccggagag-
gagacttcacag and tccacgatttcccagagaac; mIL10: gctggacaaca-
tactgctaacc and ctggggcatcacttctacca; mTGFb1: ttgcttcagctccaca-
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and ctccccacctgtcgtgtagt; mE-Cadherin: caaagtgacgctgaagtcca and
tacacgctgggaaacatgag; mZonulin-1:gggccatctcaactcctgta and agaa-
gggctgacgggtaaat; m18S: accgcagctaggaataatgga and gcctcagttcc-
gaaaacca; mGP-BAR1: ggcctggaactctgttatcg and gtccctcttggctc-
ttcctc; h18S: cggctaccacatccaaggaa and gctggaattaccgcggct;
hGPBAR1: cactgttgtccctcctctcc and acactgctttggctgcttg.
In silico and docking studies
Generation of in silico model of GP-BAR1 and docking studies of
ciprofloxacin and TLCA in the ligand binding site of GP-BAR1
were carried out as described in Materials and Methods S1,
accordingly to previously published methods [14–21].
In vitro testing of ciprofloxacin and TLCA on spleen
monocytes and GLUTag cells
Mouse monocytes were isolated from spleens of GP-BAR1 wild-
type and null mice (C57BL/6BJ6 background) by positive
selection using magnetic cell sorting according to the manufac-
turer’s instructions (Miltenyi Biotec) and then cultured in complete
RPMI medium as described previously [11,12]. GLUTag cells
were cultured in DMEM with high (4.5 g/litre), glutamine, FBS at
10% and standard P/S antibiotics [22]. GLUTag cells, were
treated with increasing concentrations of ciprofloxacin and
intracellular cAMP concentration ([cAMP]i) evaluated by an
EIA kit (Arbor Assays, direct Cyclic AMP assay kit. Spleen
monocytes were treated for 309 with 10 mM ciprofloxacin or
TLCA and intracellular cAMP concentration ([cAMP]i) evaluated
by an EIA kit (Arbor Assays, direct Cyclic AMP assay kit.
To assess anti-inflammatory activities of ciprofloxacin, spleen-
derived monocytes from wild type and GP-BAR1
2/2 were
challenged with LPS, 1 mg/ml for 24 hours and TNFa mRNA
levels assessed by RT-PCR. RAW 264.7 cells were cultured in
DMED with high (4.5 g/litre), glutamine, FBS at 10% and
standard P/S antibiotics. RAW cells were treated with increasing
concentrations of oleanolic acid [15,17], and [cAMP]I measured
as described above. In addition, RAW cells were challenged with
LPS, 1 mg/ml for 24 hours and in the presence of oleanolic acid
(1 mM) or TLCA (50 mM) and TNFa released in supernatants
assessed by Multi-analyte ELISArray Kit (SAbiosciences A,
Qiagen).
In silico studies and homology modeling
See Materials and Methods S1.
Statistical Analysis
GraphPad Prism version 3.0 was used for graphics and
statistical analyses (GraphPad Software, San Diego, CA, USA).
Data are expressed as mean 6 SEM. For comparison of more
than two groups one-way ANOVA followed by the Tukey test
was used. An associated probability,0.05 was considered
significant. The Mann-Whitney test was used to compare two
groups of data. An associated probability,0.05 was considered
significant.
Results
GP-BAR1 is expressed in the colon and its expression is
modulated by inflammation
To gain insight on the role of GP-BAR1 in regulating intestinal
homeostasis, we have first investigated the expression of this
receptor in intact colons. Despite the macroscopic inspection of
colons obtained from GP-BAR1 mice at the age of 3 (not shown)
and 12 months revealed no obvious macroscopic abnormalities, a
significant reduction in colon cellularity and crypt distortion was
detected at the histopathology analysis of 12-month old GP-
BAR1
2/2 mice (Figure 1A). Analysis of GP-BAR1 expression by
immuno-histochemistry (Figure 1A, lower panel) demonstrates a
diffuse expression of the receptor in enteric ganglia, muscolaris
externa and muscolaris mucosa, enterocytes and mononuclear cells
migrated into the lamina propria. No staining was detected when
the primary antibody was omitted (Figure 1A, lower right panel).
In addition, GP-BAR1 deficiency results in a marked reduction in
the number of alcian blue positive mucous cells in the crypt and
impairment of their maturation, i.e. a marked reduction along the
vertical axis of the crypt (Figure 1B). These changes, as illustrated
in Figure 1C and D, correlate with a disarrayed molecular
architecture of colonic tight junctions. Indeed by RT-PCR analysis
we detected a robust increase in the expression of zonulin-1
mRNA in the colon of GP-BAR1
2/2 mice, however this increased
gene expression associated with an altered sub-cellular distribution
of the protein. Thus, while staining for zonulin-1 was uniformly
distributed along the apical border of colonocytes and the vascular
endothelial cells in wild type mice, a discontinuous pattern was
observed in GP-BAR1
2/2 mice (Figure 1D, arrow). GP-BAR1
2/2
mice had also a significant reduction in the expression of occluding
mRNA (Figure 1C, n=6; P,0.05), while no changes were detected
in the expression of E-cadherin. This dysregulated architecture of
tight junctions in GP-BAR1
2/2 mice associated with a robust
increase in intestinal permeability as assessed by measuring
dextrane FITC concentrations in the blood (Figure 1C; n=6–8;
P,0.05 versus naive). Phenotypic characterization of mononuclear
cells isolated from the lamina propria of wild type and GP-BAR1
2/2
mice revealed no significant changes in total cell numbers nor in the
cell phenotype, with the exception of a modest increase in the
number of CD8
+ cells (Figure S1; n=6; P,0.05).
Because changes in the intestinal permeability might result in an
increased tendency to develop injury toward luminal antigens, we
have challenged 3-month old wild type and GP-BAR1
2/2 mice
with DSS, a barrier braking agent. The severity of DSS-induced
colitis was exacerbated in GP-BAR1
2/2 resulting in a higher
diarrhea and colonic macroscopic injury scores and intestinal
permeability (Figure 2A–C). A short course of 5% DSS in drinking
water associated with a significant upregulation of colonic
expression of GP-BAR1, mRNA and protein (Figure 2D and E),
in wild type mice. Increase in GP-BAR1 expression associated
with the influx of GP-BAR1 positive mononuclear cells in the
colonic lamina propria (Figure 2D, lower panel and inset).
Histopathology analysis of alcian blue-stained colons revealed a
severe loss of mucous cells in GP-BAR1
2/2 mice exposed to DSS
(Figure 2F). In addition, DSS administration resulted in a robust
dysregulation of colon expression of zonulin-1, occludin and E-
cadherin mRNAs in both wild type and GP-BAR1
2/2 mice
(Figure S2). Changes in colitis severity were not due different
exposure to DSS or reduced daily food and water intakes. Indeed
food and water intakes in mice administered DSS were:
4,2560.3 g/mouse and 6,260.5 ml/mouse in wild type mice,
and 4.360.4 g/mouse and 5,960.7 ml/mouse in GP-BAR1
2/2
mice (none of these values were significant).
Discovery of ciprofloxacin as GP-BAR1 agonist
Because only a limited number of GP-BAR1 ligands are
available and LCA and TLCA, the two natural ligands, increase
intestinal permeability in intact animals and intestinal monolayers
[23–25], we have carried out an in silico screening to identify novel
GP-BAR1 agonists. From this in silico study we identified
ciprofloxacin, a widely used antibiotic [26], as a potential ligand
GPBAR1 and Intestinal Epithelial Barrier
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has not yet been solved experimentally, we have carried out an
homology modeling study in order to obtain the three dimensional
structure of the receptor [14]. For this purposes we have used the
human adenosine A2 receptor [14] as template for modeling
studies and prediction of GP-BAR1 structure (Figure 3B) and for
analysis of the interactions of TLCA and ciprofloxacin with its
binding domain (Figure 3B) in order to generate a structure-
activity relationship and gain information on their binding mode
at atomic level. As shown in Figure 3B, TLCA and ciprofloxacin
accommodate on the GP-BAR1 receptor surface interacting with
specific aminoacids as further described in Data S1.
Results of docking studies were confirmed by in vitro studies in
GLUTag cells, a cell line highly enriched in GP-BAR1 [27].
Exposure to ciprofloxacin (Figure 3C) resulted in a concentration-
dependent increase of [cAMP]i with an EC50 of <8 mM (n=3).
Ciprofloxacin, 10 mM, was as effective as 10 mM TLCA (n=3).
To investigate whether these effects were GP-BAR1 dependent,
we have then tested the effect of ciprofloxacin on spleen-derived
macrophages isolated from wild type and GP-BAR1
2/2 mice.
Figure 3D and E demonstrate that exposure to ciprofloxacin,
10 mM, resulted in a 3-fold increase in [cAMP]i in GP-BAR1
+/+
(n=4; p,0.05), but not in GP-BAR1
2/2 cells. In addition, while
ciprofloxacin, 10 mM, completely inhibited TNFa release induced
by LPS in GP-BAR1
+/+ monocytes, this effect was lost in GP-
BAR1
2/2 cells (n=6; P,0.05 versus naive). Similarly to the effect
exerted on cAMP, inhibition exerted by ciprofloxacin on LPS-
induced TNFa release was concentration-dependent with an EC50
of <5 mM (n=4), data not shown.
Ciprofloxacin corrects immune dysfunction in TNBS
colitis
Balb/c are highly sensitive to TNBS induced colitis and react to
the haptenizing agent by generation of an array of inflammatory
mediators with a Th1 signature [11,12]. As illustrated in Figure 4,
systemic administration of ciprofloxacin, 30 mg/kg/day i.p., to
TNBS-injected mice protected against development of wasting
disease and local signs of inflammation as shown by attenuation of
diarrhea score and macroscopic and histopathology scores
(Figure 4A–C; n=6–8; P.0.05 versus TNBS alone). By
immuno-histochemistry high levels of expression of GP-BAR1
were detected in immune cells infiltrating the submucosa and
Figure 1. GP-BAR1 gene deletion alters colon structure and function. Panel A. Upper panels: H&E staining of colonic sections obtained
from 12-month old GP-BAR1
+/+ and GP-BAR1
2/2 mice. A significant reduction in colon cellularity and crypt distortion is observed in the colon of GP-
BAR1
2/2 mice. Lower panels: immunohistochemical analysis of GP-BAR1 in wild type mice showing expression in epithelial cells. No staining is
observed when the primary antibody is omitted. Original magnification 206and 406(insect). Panel B. Alcian blue staining of colon sections from 12-
month old mice showing a severe reduction of mucous cells and their impaired maturation in GP-BAR1
2/2 mice. Note the marked reduction of alcian
blue positive cells in the crypts. Original magnification 206. Panel C. RT-PCR analysis of mRNA expression of junctional proteins (zonulin-1, occludin
and E-cadherin) in wild type and GP-BAR1
2/2 mice (n=6; P,0.05). 12-months GP-BAR1
2/2 mice also show a significant increase in intestinal
permeability to dextrane FITC (n=6–8; P,0.05 versus naive). Panel D. Immuno-histochemical detection and immuno-fluorescence localization of
zonulin-1. The staining of the protein is increased in GP-BAR1
2/2 animals but its cells localization appears to be discontinuous (arrows). Original
magnification 206.
doi:10.1371/journal.pone.0025637.g001
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colonic expression of the GP-BAR1 mRNA increased by 2–3 folds
in TNBS treated mice (Figure 4D, E. n=6 per group, P,0.01
versus naive mice). This pattern of regulation of GP-BAR1 was
confirmed by the analysis of the expression of the receptor in colon
samples obtained from Crohn’s disease patients who underwent
right ileo-colon resection. The immune-histochemistry analysis
shown in Figure 4F, demonstrates a robust induction of GP-BAR1
expression in areas of colon infiltration by inflammatory cells. The
RT-PCR analysis shown in Figure 4F confirmed an increased
expression of GP-BAR1 mRNA in the colon of Crohn’s disease
patients compared to non inflamed colons sampled at the intact
margins of resection of colon adenocarcinomas (n=6; P,0.01).
Systemic administration of ciprofloxacin also resulted in a
robust attenuation of immune dysfunction caused by TNBS. Thus,
while exposure to TNBS caused a 20–30 fold increase in the
colonic expression of IL-6, TNFa, IL-1b and IFNc, these changes
were abrogated by co-treating mice with ciprofloxacin (Figure 4G;
n=6–8; p,0.01 versus naive and TNBS). Characterization of
LPMC by flow cytometry demonstrates that TNBS administration
associates with an increased cellularity mainly due to an influx of
CD3
+ and CD14
+ cells. The percent of CD3
+ and CD14
+ cells
increased from 12.163.2 and 4.261.2 to 23.363.1 and 13.861.0,
respectively (P,0.05 versus naive). While ciprofloxacin, had no
effect on the percentage of CD3+ cells, it caused a robust
reduction in the number of LP-infiltrating CD14
+ cells (P,0.01
versus TNBS alone). Characterization of GP-BAR1 expression in
these cells revealed that <12% of LPMC stained positively for GP-
BAR1 in naive mice. This percentage increased in response to
TNBS (Figure 5C (A–D). However, while only a small proportion
of CD3
+ cells were co-stained by GP-BAR1 antibody (<3%), a
large proportion of CD14+ cells (<85%) were GP-BAR1 positive.
These relative proportions were not changed by administration of
ciprofloxacin (Figure 5E).
Oleanolic acid, a GP-BAR1 agonist attenuates colitis
induced by TNBS
To confirm that GP-BAR1 activation was therapeutically
effective in reducing colonic inflammation we have challenged
Balb/c mice rendered colitic by TNBS treatment with oleanolic
acid (Figure 6A), a well established GP-BAR1 ligand [1–4,15,17].
Activity of oleanolic acid on GP-BAR1 was first investigated by
measuring cAMP generation in GLUTag cells. As shown in
Figure 6B, oleanolic acid caused a concentration-dependent
Figure 2. GP-BAR1 gene ablation predisposes to development of severe colitis in response to DSS in 3 months old mice C57Bl/6
mice. Panel A–C. GP-BAR1
2/2 mice develop a severe disease (n=6; P,0.05), while changes of intestinal permeability were increased in GP-BAR1
2/2
mice in comparison to wild type mice (n=10; *P,0.05 versus naive; **P,0.05 versus wild type DSS). Panel D. Immuno-histochemical detection of GP-
BAR1 expression in the colon of wild type mice challenged with DSS. GP-BAR1 is abundantly expressed in mononuclear cells infiltrating the lamina
propria.Originalmagnification206and406(inset).PanelE.ColonexpressionofGP-BAR1 mRNAinwildtypemicechallengedwithDSS(n=6;P,0.05).
Panel F. Treatment of GP-BAR1
2/2 mice with DSS results in a dramatic and diffuse loss of alcian blue-positive mucous cells. Original magnification 106.
doi:10.1371/journal.pone.0025637.g002
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acid was effective in reducing TNFa release triggered by LPS from
RAW macrophages, confirming that this agent is GP-BAR1
agonist and a TNFa inhibitor (Figure 6C; n=4; P,0.05). When
administered orally at the dose of 0.1, 1 and 10 mg/kg/day for 4
days, oleanolic acid dose-dependently attenuated development of
TNBS colitis, as measured by assessing weight loss, diarrhea and
macroscopic scores as well as expression of signature cytokines (Il-
10, TNFa and IL-6) in the colons (Figure 6D–I; n=5, P,0.05
versus TNBS alone). Taken together these data demonstrate that
GP-BAR1 ligands of chemical or natural origins are effective in
reducing inflammation caused by TNBS in wild type mice.
GP-BAR1 mediates anti-inflammatory activities of
ciprofloxacin
To investigate the role of GP-BAR1 in anti-inflammatory
activities of ciprofloxacin, we have then queried whether anti-
inflammatory properties of ciprofloxacin would be modulated by
the absence of GP-BAR1. Compared to Balb/c mice, adminis-
tration of wild type and GP-BAR1
2/2 mice on a C57BL6J
background with TNBS and DSS resulted in a mild colitis (Figure 7
(A–C) and Figure S3). TNBS-induced inflammation in wild type
mice associated with increased MPO activity, a marker of
neutrophils infiltration and increased expression of signature
cytokines including TNFa and IL-1b (n=6–8; p.0.05 versus
naive). All these effects were attenuated by ciprofloxacin (30 mg/
kg). Administration of TNBS to GP-BAR1
2/2 mice resulted in a
colitis that was partially exacerbated in comparison to that
observed in C57BL6J congenic littermates (Figure 7) and that was
resistant to treatment with ciprofloxacin, 30 mg/kg/day (n=6–8;
P,0.05 versus naive mice). The lack of efficacy of ciprofloxacin in
protecting GP-BAR1
2/2 mice was independent on its antibiotic
activity, because, as shown in Figure 7C, ciprofloxacin exerted a
comparable antibiotic activity in both mice strains. Nor different
sensitivity to the systemic antibiotic related on a different
composition of intestinal flora, because naive wild type and GP-
BAR1
2/2 mice had similar patterns of intestinal bacteria. Finally,
the failure of ciprofloxacin to attenuate colitis in GP-BAR1
2/2
mice was confirmed in a second model of inflammation, i.e. colitis
induced by DSS (Figure S3).
Figure 3. Ciprofloxacin is a GP-BAR1 ligand. Panel A. Chemical structure of taurolithocholic acid (1) a natural GP-BAR1 ligand and ciprofloxacin
(2). Panel B. The predicted GP-BAR1 three dimensional structure was used to analyze the interactions of taurolithocholic acid (lefts) and ciprofloxacin
(right) with its binding domain. Both taurolithocholic acid (purple) and ciprofloxacin (yellow) accommodates on the GP-BAR1 binding site (lower
panel). Panel C. Ciprofloxacin and TLCA increases [cAMP]i in GLUTag cells. N=4; P,0.05. Panel D. Ciprofloxacin and taurolithocholic acid , 10 mM,
caused a 2–3 fold increase in [cAMP]i in spleen-derived monocytes isolated from GP-BAR1 wild type mice (n=4–5; P,0.05), but not in cells isolated
from GP-BAR1
2/2 mice. Panel E. Ciprofloxacin, 10 mM, inhibits LPS-induced TNFa release in GP-BAR1
+/+ monocytes but not in cells isolated from GP-
BAR1
2/2 mice (n=6; P,0.05 versus naive).
doi:10.1371/journal.pone.0025637.g003
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GP-BAR1 is G protein coupled receptor activated by secondary
bile acids with LCA and TLCA acting bona fide as the physiological
ligands for the receptor with an EC50, calculated in CHO cells
t r a n s f e c t e dw i t ht h eh u m a nG P - B A R 1 ,o f<0.5 and <0.3 mM,
respectively [3,4]. In the human gastrointestinal tract the GP-BAR1
gene is expressed at the highest levels in the stomach, ileum and
colon, but its functional role is largely unexplored. Outside the
gastrointestinal tract, the highest level of expression is found in the
spleen and resting monocytes. In vitro studies have provided
compelling evidence that exposure of blood-derived human CD14+
cells to GP-BAR1 agonists results in a negative regulation of
macrophage’s effector functions and increased [cAMP]i [3,4,8,28].
With this background in mind we have interrogated GP-BAR1
deficient mice to gain insights on the functional role the receptor
exerts in regulating intestinal homeostasis. Results from these
experiments strongly argue for a mechanistic role for GP-BAR1 in
regulating intestinal barrier integrity. Thus, mice lacking GP-BAR1
develop an altered colonic histopatology with a severe alteration in
distribution and maturation kinetic of mucous cells as shown by
results of alcian blue staining. In addition, GP-BAR1 deficiency
results in disruption of molecular architecture of colonic tight
junctions that develop with age. Thus, not only the expression of
genes encoding for zonulin 1 and occludin was markedly disturbed in
GP-BAR1
2/2 mice, but there was also a significant alteration of
subcellular localization of zonulin-1 as demonstrated by immuno-
histochemistry. This distortion in the molecular organization of
intestinal tight junctions manifests phenotypically with an increased
intestinal permeability, that become statistically different from
congenic littermates at the age of 12 months. Because alterations in
the tight junction architecture is a well recognized hallmark of
intestinal inflammation, these data support the notion that GP-BAR1
provides regulatory signals to intestinal epithelial cells.
Figure 4. Effects of ciprofloxacin on colitis. Panel A. Systemic administration of ciprofloxacin (30 mg/kg/day) protects against development of
signs and symptoms of colitis induced by TNBS in GP-BAR1
+/+ mice (n=6–8; p,0.05 versus naı ¨ve). Panel B and C. Ciprofloxacin attenuates
histopathology changes induced by TNBS (n=6–8; p,0.05 versus naı ¨ve). Original magnification 106 and 206. Panel D and E. TNBS colitis
associates with a robust influx of GP-BAR1 positive cells into the lamina propria of the colon and increased expression of GP-BAR1 mRNA.
Mononuclear cells infiltrating the lamina propria show a robust staining for GP-BAR1 (arrow). This upregulation was partially attenuated by
ciprofloxacin. Panel F. Immuno-hisyochemistry and RT-PCR analysis of GP-BAR1 expression in the colon of Crohn’s disease patients. n=6; P,0.05
versus control subjects. Panel G. RT-PCR analysis of expression of signature cytokines in wild type mice exposed to TNBS. Treatment with
ciprofloxacin reduces significantly the expression of IL-6, TNF-a, IL-1b and INF-c mRNAs (n=6; P,0.05).
doi:10.1371/journal.pone.0025637.g004
GPBAR1 and Intestinal Epithelial Barrier
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25637Little is known on the role of GP-BAR1 on the pathogenesis of
human IBDs. However, mapping of locus at chromosome 2q35 i.e.
a locus known to be associated with ulcerative colitis (UC) and
sclerosing cholangitis (PSC), has revealed an overall association
between the GP-BAR1 single-nucleotide polymorphism,
rs11554825, and PSC (odds ratio=1.1; p=0.010) and UC (odds
ratio=1.19, p=8.5610
27), thought that strong linkage disequi-
librium precluded further demarcation of GP-BAR1 from
neighboring genes [14]. Because rs11554825 polymorphism is a
loss-of-function mutation of the GP-BAR1 (TGR5) gene, and an
altered intestinal permeability occurs in several genetic abnormal-
ities in IBDs, present results provide a further support to a
mechanistic role of GP-BAR1 loss of function mutations in the
pathogenesis of IBDs.
While deficiency to maintaining intestinal organization in GP-
BAR1
2/2 manifests with age, GP-BAR1
2/2 mice were more
susceptible than their congenic littermates to develop a colitis
when challenged with a barrier braking agent. Thus, at the age of
3 months, when no histopathology abnormalities could be
detected, challenging GP-BAR1
2/2 mice with DSS resulted in a
robust exacerbation of local signs of colitis. These changes become
apparent after a short course of DSS and were not mirrored by
major immunological abnormalities, but a striking increase in
intestinal permeability in response to DSS was the major
biomarker detected in GP-BAR-1
2/2 mice in this setting.
An important observation we made in this study was that, not
only the absence of GP-BAR1 increases the susceptibility to
develop an intestinal inflammation in response to a barrier braking
agent, but that the expression of the receptor is robustly modulated
by inflammation in rodent models of colitis and Crohn’s disease
patients. Interestingly the immuno-histochemistry analysis, cor-
roborated by gene expression data, indicates that despite its
localization on apical and mucous cells, a significant increase of
GP-BAR1 signals in inflamed colons occurs almost exclusively
from mononuclear cell infiltrating the colonic lamina propria in
mice or from inflammatory cells in Crohn’s patients. Colitides
induced by TNBS and DSS in wild type Balb/c mice associate
with a robust influx of mononuclear cells in the lamina propria. A
large percentage of these cells stained positively for GP-BAR1 and
the phenotypic characterization of LPMC in the TNBS colitis
demonstrates that a <90% of CD14
+ cells were GP-BAR1
positive, while only a small proportion of CD3+ cells expressed the
receptor strongly indicating a role for GP-BAR1 in regulating cells
of innate immunity.
In the search for ligand that could be exploited therapeutically
as GP-BAR1 ligand, we have identified ciprofloxacin as a GP-
Figure 5. Flow-cytometry analysis of GP-BAR1 expression in unfractioned lamina propria mononuclear cells (LPMC) and LPMC-
derived CD3+(A) and CD14+ cells (B) obtained from colons of naı ¨ve mice and mice administered TNBS alone and in combination
with ciprofloxacin (n=6; *P,0.05 versus naı ¨ve mice, **P,0.05 versus TNBS mice). Panel C. Bar graphs of quantitative expression of GP-
BAR1 in unfractioned LPMC. Panel D. Flow cytometry histogram showing GP-BAR1 protein expression in LPMC in different treatment settings. Panel
E. Representative Dot plot (forward scatter/ side Scatter) of LMPC obtained from colons of naı ¨ve and colitic mice treated with ciprofloxacin.
Representative dot plot graphs of relative expression of GP-BAR1 CD3+ and CD14+ cell obtained from LPMC. The numerical values indicate the means
6 SE of % double positive cells.
doi:10.1371/journal.pone.0025637.g005
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infections due to Gram negative bacteria in Crohn’s disease. In
addition, ciprofloxacin has been shown to increase [cAMP]i in
monocytes and macrophages, and by this mean to exert a counter-
regulatory effect on cytokine production triggered by LPS [28]. So
far the molecular mechanisms mediating these effects were left
unknown. By in silico screening, docking calculation and in vitro
experiments we have shown that ciprofloxacin functions as GP-
BAR1 agonist. Indeed, not only ciprofloxacin entertains mean-
ingful interaction with key aminoacids in the binding site of GP-
BAR1, as demonstrated by docking experiments, but it triggers
changes in [cAMP]i in GLUTag cells, an L-like cell line generated
from an entero-endocrine tumor and highly enriched in GP-
BAR1, and in spleen-derived monocytes [2–4,27]. These effects
were lost in GP-BAR1
2/2 cells, striking indicating that these non-
antibiotic effects require the presence of this receptor.
When used to treat colonic inflammation induced by TNBS
administration to Balb/c mice, ciprofloxacin effectively protected
against development of local signs of colitis and markedly reduced
local generation of inflammatory mediators including IL-1b, IL-6,
IFNc and TNFa. Flow cytometry characterization of mononu-
clear cells infiltrating the lamina propria revealed that, in
comparison with animals exposed to TNBS alone, treatment with
ciprofloxacin was effective in reducing the number of CD14+ cells
from <15% to <7%. Because expression of GP-BAR1 is detected
in <90% of CD14+ cells isolated from the lamina propria and
ciprofloxacin was administered systemically, these data strongly
argue that anti-inflammatory and immuno-regulatory activities of
ciprofloxacin are mediated through local and/or systemic
activation of GP-BAR1 in CD14+ cells.
While effective at treating abdominal infections in Crohn’s
disease patients, antibiotics are recognized to carry on a minor role
Figure 6. Anti-inflammatory effects of oleanolic acid. Oleanolic acid (panel A), a natural GP-BAR1 agonist, exerts anti-inflammatory activity
and protects against colitis development in wild type mice. Panel B. Oleanolic acid increases [cAMP]i in RAW cells in a concentration-dependent
manner. N=4; *P,0.05 versus basal. Panel C. Oleanolic acid reduces TNFa release from murine macrophages exposed to LPS. N=4. *P,0.05;
**P,0.05 versus LPS alone. Panel D–F. Oleanolic acid dose-dependently attenuates sign and symptoms of colitis induced by TNBS in wild type mice.
N=5 per group. *P,0.05 versus naive: ** P,0.05 versus TNBS alone. Panel G–I. Oleanolic acid treatment leads to a significant reduction in the
colonic expression of inflammatory mediators including TNF-a and IL-6. *P,0.05 versus naive: ** P,0.05 versus TNBS alone.
doi:10.1371/journal.pone.0025637.g006
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in preventing disease relapse in this setting is poorly explained by
pharmacological data. Here, we have made the surprising
observation that anti-inflammatory and immune-modulatory
actions of ciprofloxacin are lost in GP-BAR1
2/2 mice. Interro-
gation of GP-BAR1
2/2 mice rendered colitic by TNBS or DSS
shows that ciprofloxacin looses an important component of its
activity when administered to mice that lack this receptor. In both
models, ciprofloxacin failed to protect against development of
colitis and failed to attenuate colonic influx of neutrophils or
expression of signature cytokines such as TNFa and IL-1b in a
GP-BAR1-dependent manner. These effects are unrelated to its
antibiotic activity, because systemic administration of ciprofloxacin
to wild type and GP-BAR1
2/2 mice caused similar patterns in
fecal contents of Enterobacter, Staphilococcus and Enteroccocus faecalis
species. Because expression of GP-BAR1 in Crohn’s disease might
change over time, it could be speculated that analysis of GP-BAR1
expression could help to identify specific subsets of patients that
might respond to this agent. Specific clinical data are needed to
confirm this hypothesis.
One important observation we made in this study is in addition
to ciprofloxacin, oleanolic acid a well characterized GP-BAR1
agonist [15,17] was also effective in attenuating colitis induced by
TNBS. These data strongly argue in favour of a pharmacologically
relevant role of GP-BAR1 in modulating colonic inflammation.
In summary, we have shown that GP-BAR1 is involved in
regulating intestinal homeostasis and that its absence manifests by
an increased intestinal permeability and enhanced susceptibility to
develop colitis in response to barrier braking agents. In addition,
we have demonstrated that expression of GP-BAR1 increases in
response to inflammation in rodent models of colitis and in
inflamed tissues obtained from Crohn’ disease patients. Finally, we
have discovered that ciprofloxacin, a widely used antibiotic, is a
GP-BAR1 agonist and that activation of GP-BAR1 with this agent
or oleanolic acid, a natural GP-BAR1 ligand, attenuates colon
inflammation in rodent models of colitis.
Supporting Information
Figure S1 Flow cytometry analysis of lamina propria
mononuclear cells isolated from wild type and GP-
BAR1
2/2 mice. There was no significant difference in the total
number of mononuclear cells infiltrating the lamina propria nor in
the cells suptypes, with the exception of a in the percentage of
Figure 7. Anti-inflammatory activities of ciprofloxacin are GP-BAR1 dependent. Panel A. Ciprofloxacin fails to attenuates colitis induced
by TNBS in GP-BAR1
2/2 mice. Colitis was induced by administering TNBS to GP-BAR1
+/+ and GP-BAR1
2/2 mice on a C57BL6J background. Treatment
with TNBS results in epithelial degeneration and in intense inflammatory infiltrate. Co- treatment with ciprofloxacin, 30 mg/kg/day, reduces
inflammatory infiltrate and epithelial degeneration in wild type mice but not in GP-BAR1
2/2 mice. Panel B. Ciprofloxacin, 30 mg/kg/day, failed to
attenuates signs and symptoms of colitis and expression of signature cytokines in GP-BAR1
2/2 mice challenged with TNBS. (n=6–8; p.0.05 versus
naı ¨ve; **P,0.05 versus TNBS). Panel C. Systemic administration of ciprofloxacin exerts a comparable antibiotic effect in GP-BAR1
+/+ and GP-BAR1
2/2
mice (n=5 mice per group). Values are not statistically different.
doi:10.1371/journal.pone.0025637.g007
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2/2 mice compared to GPBAR1
+/+ mice (n=
4; *P,0.05).
(TIF)
Figure S2 Colon expression of gene encoding for tight
junction proteins. (A). Naı ¨ve GP-BAR1
2/2 mice express
higher levels of Zonulin 1 mRNA than wild type and exposure
to DSS amplify these changes. (B). Expression of E-cadherin and
occludin mRNA increases in response to DSS, but there is no
difference in its up-regulation between wild type and GP-BAR1
2/2
mice challenged with DSS. N=6; *P,0.05 versus naive; ** P,0.05
versus DSS.
(TIF)
Figure S3 Anti-inflammatory activities of ciprofloxacin
is lost in GP-BAR1
2/2 mice challenged with DSS. GP-
BAR12/2 mice treated with DSS show an exacerbated
colonic inflammation as observed by enhanced loss of
body weight, colitis score, macroscopic score (Pane A–
C). DSS treatment also results in a significant increase in colon
content of MPO (Panel D). All these changes are attenuated by
the administration of ciprofloxacin (30 mg/kg) in wild type mice
but not GP-BAR1
2/2 mice. N=6–8 mice per group. *P,0.05
versus naive.**P,0.05 versus DSS. (Panel E) E&E stained colon
sections from GP-BAR12/2 mice and wild type mice treated
with DSS alone or in combination with ciprofloxacin Magnifica-
tion 406. Treatment with DSS results in epithelial degeneration
and can be observed an intense inflammatory infiltrate that is
enhanced in GP-BAR1
2/2 mice compared to wild type mice, co-
treatment with ciprofloxacin reduces inflammatory infiltrate and
epithelial degeneration in wild type mice but not in GP-BAR1
2/2
mice, as confirmed by microscopic injury score (Panel F). DSS
treatment increases the colon expression of signature cytokines
such as IL-1b and TNFa both in wild type and GP-BAR12/2.
Co-treatment with ciprofloxacin attenuates the expression of these
cytokines in wild type but not in GP-BAR1
2/2 mice (n=6–8;
*p,0.05 versus naı ¨ve; **p,0.05 versus wild type DSS treated
mice) (E).
(TIF)
Materials and Methods S1 In silico studies and GP-BAR1
homology modeling.
(DOC)
Data S1 Results of docking calculation of interaction of
ciprofloxacin and TLCA with GP-BAR1 binding site.
(DOC)
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